Cargando…
Role of RANKL inhibition in osteoporosis
When the rate of bone resorption exceeds that of bone formation, destruction of bone tissue occurs, resulting in a fragile skeleton. The clinical consequences, namely osteoporosis and fragility fractures, are common and costly problems. Treatments that normalize the balance of bone turnover by inhib...
Autor principal: | McClung, Michael |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924518/ https://www.ncbi.nlm.nih.gov/pubmed/17634142 http://dx.doi.org/10.1186/ar2167 |
Ejemplares similares
-
Emerging Therapies for Osteoporosis
por: McClung, Michael R.
Publicado: (2015) -
Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018) -
Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017) -
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009) -
Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis
por: Huang, Dane, et al.
Publicado: (2022)